Several large clinical trials have demonstrated that the inhibition of RAAS reduced the incidence of diabetes in patients with HF and/or risk for coronary artery disease probably through different pathways including increased perfusion of insulin-sensitive muscles and tissues with improved cellular insulin sensitivity and increased insulin secretion (17–19). This evidence concerns the gene INS and coronary artery disorder.